BioAge Labs (BIOA) vs NervGen Pharma (NGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
NervGen Pharma (NGEN) has outperformed BioAge Labs (BIOA) over the past year, losing 35.0% versus a loss of 50.5%. NervGen Pharma is the larger company by market cap ($198.6 million vs $196.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIOA | NGEN |
|---|---|---|
| Share price | $4.28 | $1.85 |
| Market cap | $196.67M | $198.55M |
| 1-day change | -9.13% | -3.91% |
| YTD return | -67.65% | -67.05% |
| 1-year return | -50.52% | -35.04% |
| 5-year return | — | -9.56% |
| EPS (TTM) | $-2.56 | $-0.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $8.99M | — |
| Net income (latest FY) | $-80.61M | — |
| Operating margin | -1031.46% | — |
| Net margin | -896.11% | — |
| 52-week high | $25.96 | $6.30 |
| 52-week low | $4.24 | $1.28 |
| Distance from 52-week high | -83.51% | -70.71% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +572.43% | +442.01% |
| Average volume | 740.06K | 621.66K |
| Shares outstanding | 45.95M | 107.62M |
| Employees | 60 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NGEN has outperformed BIOA by 15.5 percentage points over the past year.
About BioAge Labs
BIOA stock →BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging.
Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees
About NervGen Pharma
NGEN stock →NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
BIOA vs NGEN FAQ
Which is bigger, BioAge Labs or NervGen Pharma?
NervGen Pharma (NGEN) is larger, with a market capitalization of $198.55M compared with $196.67M for BioAge Labs (BIOA).
Which stock has performed better over the past year, BIOA or NGEN?
NGEN returned -35.04% over the past 12 months, compared with -50.52% for BIOA (price return, excluding dividends). Past performance does not predict future results.
Are BioAge Labs and NervGen Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.